Benefits of intermittent/continuous androgen deprivation in patients with advanced prostate cancer

Authors

  • Horia Muresanu

DOI:

https://doi.org/10.15386/cjmed-594

Keywords:

androgen deprivation, GNRH antagonist, Qol

Abstract

Background and aims:

Huggins described in 1941 the effect of castration on prostate cancer. Gonadotropin-releasing hormone (GNRH) analogue were introduced in 1985. Complete androgen blocade (association of GNRH analogue with antiandrogen) was introduced by Fernand Labrie to achieve supression of suprarenalian testosterone. Long time androgen deprivation lead to androgen independence of prostate cancer cell.

Our principal aim was to demonstrate longer survival rates on prostate cancer patients with intermittent androgen deprivation.

Methods:

  • 82 patients were enrolled at the Urology Deparment of West University „Vasile Goldiș” Arad in two groups with continous and intermittent androgen deprivation.
  • Treatment efficiency was assesed by the level of testosterone and PSA.
  • Adverse events (AE) and serious adverse events were reported  according to Common Terminology Cryteria of Adverse Events (CTCAE) of the National Cancer Institute  (NCI).

Results:

  • Evolution towards castrate resistant prostate cancer: 12.5% from the intermittent androgen deprivation group and 23.8% from the continues androgen deprivation group
  • Mortality rate: 15% of patients from the intermittent androgen deprivation group; 19% of patients from the continue androgen deprivation group

 

Conclusions:

1. Better quality of life (Qo)l in periods without treatment due to testosteron recovery; 2. Less AE’s and methabolic syndrom (MS) related complications; 3. Better survival and longer time of disease control and 4. Cost reduction

Author Biography

Horia Muresanu, West University Vasile Goldiș Arad

Faculty of Medicine, Farmacy and Dentistry

Downloads

Additional Files

Published

2016-07-31

How to Cite

1.
Muresanu H. Benefits of intermittent/continuous androgen deprivation in patients with advanced prostate cancer. Med Pharm Rep [Internet]. 2016 Jul. 31 [cited 2025 Oct. 5];89(3):419-22. Available from: https://medpharmareports.com/index.php/mpr/article/view/594

Issue

Vol. 89 No. 3 (2016)

Section

Original Research

License

The authors are required to transfer the copyright of the published paper to the journal. This is done by agreeing to sign the Copyright Assignment Form. Whenever the case, authors are also required to send permissions to reproduce material (such as illustrations) from the copyright holder.

 Creative Commons License
The papers published in the journal are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.